摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-{3-[4-(3-chlorophenyl)piperazine-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one | 496921-70-1

中文名称
——
中文别名
——
英文名称
1-{3-[4-(3-chlorophenyl)piperazine-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one
英文别名
1-{3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one;1-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-6,7-dihydro-5H-indol-4-one
1-{3-[4-(3-chlorophenyl)piperazine-1-yl]propyl}-1,5,6,7-tetrahydroindol-4-one化学式
CAS
496921-70-1
化学式
C21H26ClN3O
mdl
——
分子量
371.91
InChiKey
QOVVILKXCUCREP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    28.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Tetrahydroindolone and purine derivatives linked to arylpiperazines
    申请人:Spectrum Pharmaceuticals, Inc.
    公开号:US06770638B2
    公开(公告)日:2004-08-03
    Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.
    本发明揭示了含有与芳基哌嗪及其衍生物相连的四氢吲哚酮的制药复合物组合物。具体地,揭示了用于治疗抗精神病障碍的复合物组合物。本发明中揭示的复合物组合物能够有效地缓解症状和治疗精神疾病,而不会导致认知功能下降。通常,复合物化合物由两个部分组成,部分A和部分B,其中四氢吲哚酮包含一个部分A,通过连接子L连接到一个部分B,其中B是芳基哌嗪基团。复合物化合物通过与GABA、血清素和多巴胺受体的相互作用提供抗精神病活性。具有综合活性的复合分子将提供治疗精神和神经疾病而不会导致认知障碍。
  • [EN] TETRAHYDROINDOLONE AND PURINE DERIVATIVES LINKED TO ARYLPIPERAZINES<br/>[FR] DERIVES DE TETRAHYDROINDOLONE ET DE PURINE LIES A DES ARYLPIPERAZINES
    申请人:NEOTHERAPEUTICS INC
    公开号:WO2003011396A1
    公开(公告)日:2003-02-13
    Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.
    本发明揭示了包含与芳基哌嗪及其衍生物连接的四氢吲哚酮的药物复合物组合物。具体地,揭示了用于治疗抗精神病障碍的复合物组合物。本发明揭示的复合物组合物可以有效地改善症状并治疗精神疾病,而不会导致认知功能下降。一般来说,复合物化合物由两个部分组成,部分A和B,其中四氢吲哚酮包含一个部分A通过连接子L连接到一个部分B,其中B是芳基哌嗪基团。复合物化合物通过与GABA、血清素和多巴胺受体相互作用提供抗精神病活性。具有结合活性的复合分子将提供治疗精神和神经疾病而不会导致认知障碍。
  • TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS
    申请人:Helton David
    公开号:US20090156609A1
    公开(公告)日:2009-06-18
    Tetrahydroindolone and aryl piperazine derivatives for use in treating post-traumatic stress disorder and acute stress disorder.
    四氢吲哚酮和芳基哌嗪衍生物用于治疗创伤后应激障碍和急性应激障碍。
  • TETRAHYDROINDOLONE AND PURINE DERIVATIVES LINKED TO ARYLPIPERAZINES
    申请人:Neotherapeutics, Inc.
    公开号:EP1412028A1
    公开(公告)日:2004-04-28
  • TETRAHYDROINDOLONE DERIVATIVES LINKED TO ARYLPIPERAZINES
    申请人:Spectrum Pharmaceuticals, Inc.
    公开号:EP1412028B1
    公开(公告)日:2007-10-17
查看更多